Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical MV-NIS in Urothelial Carcinoma
NCT03171493Phase 1Completed
- Sponsor
- Vyriad
- Start
- Jul 2018
- Primary completion
- Feb 2021
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MV-NIS in urothelial carcinoma (UC), sponsored by Vyriad. Primary endpoint: Number of participants with intravesical MV-NIS treatment related adverse events. Started Jul 2018; status: completed.
02
Drugs
MV-NIS
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03171493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171493.